See up to 3 months of PHVS. The 7-day demo opens the 1M and 3M ranges and puts PHVS on your watchlist.
Start 7-day demoLatest PHVS insider trades
About Pharvaris N.V. (PHVS)
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
- 129
- 2021
- XNAS
PHVS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 19 | 559,502 | $20.41M |
| Option exercise | 28 | 981,474 | |
| Tax withholding / forfeiture | 6 | 678 | |
PHVS insider transactions (Form 4)
7456 Form 4 filings on record, the earliest from Apr 3, 2026, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Peng Lu - Officer | Tax withholding / forfeiture | Common Stock | 117 footnote F1 | $32.20 | $4K | |
| ||||||
| Peng Lu - Officer | Tax withholding / forfeiture | Common Stock | 109 footnote F1 | $31.51 | $3K | |
| ||||||
| Open-market sale | Common Stock | 2,670 | $30.87 footnote F1 | $82K | ||
| ||||||
| Open-market sale | Common Stock | 9,667 footnote F1 | $30.29 footnote F2 | $293K | ||
| ||||||
| Option exercise | Common Stock | 1,829 | $20.00 | $37K | ||
| Open-market sale | Common Stock | 1,829 | $30.60 footnote F2 | $56K | ||
| Option exercise | Common Stock | 5,501 | $20.00 | $110K | ||
| Open-market sale | Common Stock | 5,501 | $30.74 footnote F3 | $169K | ||
| Option exercise | Stock Option (Right to Buy) | 1,829 | $0.00 | - | ||
| Option exercise | Stock Option (Right to Buy) | 5,501 | $0.00 | - | ||
| ||||||
| Open-market sale | Common Stock | 10,000 | $30.31 footnote F1 | $303K | ||
| ||||||
| Option exercise | Common Stock | 10,000 | $8.05 | $81K | ||
| Open-market sale | Common Stock | 10,000 | $29.32 footnote F2 | $293K | ||
| Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | ||
| ||||||
| Berndt Modig - Officer | Open-market sale | Common Stock | 2,292 | $29.22 footnote F1 | $67K | |
| ||||||
| Open-market sale | Common Stock | 4,667 | $29.82 footnote F2 | $139K | ||
| Option exercise | Common Stock | 5,333 | $22.31 | $119K | ||
| Open-market sale | Common Stock | 5,333 | $29.83 footnote F1 | $159K | ||
| Option exercise | Stock Option (Right to Buy) | 5,333 | $0.00 | - | ||
| ||||||
| Stefan Andreas Abele - Officer | Open-market sale | Common Stock | 8,748 | $29.82 footnote F1 | $261K | |
| ||||||
| Wim Souverijns - Officer | Open-market sale | Common Stock | 10,000 | $29.92 footnote F2 | $299K | |
| ||||||
| Peng Lu - Officer | Tax withholding / forfeiture | Common Stock | 109 footnote F1 | $30.09 | $3K | |
| Peng Lu - Officer | Tax withholding / forfeiture | Common Stock | 117 footnote F2 | $29.95 | $4K | |
| ||||||
| Peng Lu - Officer | Option exercise | Common Stock | 14,166 | $2.59 | $37K | |
| Peng Lu - Officer | Open-market sale | Common Stock | 14,023 | $30.16 footnote F3 | $423K | |
| Peng Lu - Officer | Open-market sale | Common Stock | 143 | $31.00 | $4K | |
| Peng Lu - Officer | Option exercise | Stock Option (Right to Buy) | 14,023 | $0.00 | - | |
| Peng Lu - Officer | Option exercise | Stock Option (Right to Buy) | 143 | $0.00 | - | |
| ||||||
| Open-market sale | Common Stock | 3,830 | $30.07 footnote F2 | $115K | ||
| Open-market sale | Common Stock | 28,400 | $30.30 footnote F3 | $861K | ||
| Open-market sale | Common Stock | 670 | $31.03 footnote F4 | $21K | ||
| ||||||
| Anne Lesage - Officer | Option exercise | Common Stock | 3,700 | $2.59 | $10K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 3,700 | $30.08 footnote F2 | $111K | |
| Anne Lesage - Officer | Option exercise | Common Stock | 3,700 | $2.59 | $10K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 3,700 | $30.26 | $112K | |
| Anne Lesage - Officer | Option exercise | Common Stock | 18,000 | $8.05 | $145K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 18,000 | $30.26 | $545K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 3,700 | $30.06 footnote F2 | $111K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 19,200 | $30.26 footnote F5 | $581K | |
| Anne Lesage - Officer | Option exercise | Stock Option (Right to Buy) | 3,700 | $0.00 | - | |
| Anne Lesage - Officer | Option exercise | Stock Option (Right to Buy) | 3,700 | $0.00 | - | |
| Anne Lesage - Officer | Option exercise | Stock Option (Right to Buy) | 18,000 | $0.00 | - | |
| ||||||
| Peng Lu - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Peng Lu - Officer | Option exercise | Common Stock | 3,733 | $2.59 | $10K | |
| Peng Lu - Officer | Open-market sale | Common Stock | 3,733 | $30.06 footnote F2 | $112K | |
| Peng Lu - Officer | Option exercise | Common Stock | 15,000 | $2.59 | $39K | |
| Peng Lu - Officer | Open-market sale | Common Stock | 15,000 | $30.24 footnote F3 | $454K | |
| Peng Lu - Officer | Option exercise | Stock Option (Right to Buy) | 3,733 | $0.00 | - | |
| ||||||
| Open-market sale | Common Stock | 7,000 | $30.05 footnote F2 | $210K | ||
| Open-market sale | Common Stock | 100 | $30.03 | $3K | ||
| ||||||
| Anne Lesage - Officer | Open-market sale | Common Stock | 100 | $30.03 | $3K | |
| Anne Lesage - Officer | Option exercise | Common Stock | 500 | $2.59 | $1K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 500 | $30.00 | $15K | |
| Anne Lesage - Officer | Option exercise | Common Stock | 7,000 | $8.05 | $56K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 7,000 | $30.05 footnote F2 | $210K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 7,000 | $30.05 footnote F2 | $210K | |
| Anne Lesage - Officer | Open-market sale | Common Stock | 100 | $30.03 footnote F3 | $3K | |
| Anne Lesage - Officer | Option exercise | Common Stock | 100 | $2.59 | $259 | |
| Anne Lesage - Officer | Option exercise | Stock Option (Right to Buy) | 500 | $0.00 | - | |
| Anne Lesage - Officer | Option exercise | Stock Option (Right to Buy) | 7,000 | $0.00 | - | |
| Anne Lesage - Officer | Option exercise | Stock Option (Right to Buy) | 100 | $0.00 | - | |
| ||||||
| Peng Lu - Officer | Option exercise | Common Stock | 7,001 | $2.59 | $18K | |
| Peng Lu - Officer | Open-market sale | Common Stock | 7,001 | $30.05 footnote F2 | $210K | |
| Peng Lu - Officer | Option exercise | Common Stock | 100 | $2.59 | $259 | |
| Peng Lu - Officer | Open-market sale | Common Stock | 100 | $30.03 footnote F3 | $3K | |
| Peng Lu - Officer | Option exercise | Stock Option (Right to Buy) | 7,001 | $0.00 | - | |
| Peng Lu - Officer | Option exercise | Stock Option (Right to Buy) | 100 | $0.00 | - | |
| ||||||
| Peng Lu - Officer | Tax withholding / forfeiture | Common Stock | 226 footnote F1 | $28.78 | $7K | |
| ||||||
| Berndt Modig - Officer | Open-market sale | Common Stock | 2,292 | $28.60 footnote F1 | $66K | |
| ||||||
| Tax withholding / forfeiture | Common Stock | 548 | $26.63 | $15K | ||
| Berndt Modig - Officer | Open-market sale | Common Stock | 23,133 | $27.74 footnote F1 | $642K | |
| Berndt Modig - Officer | Open-market sale | Common Stock | 200 | $28.42 footnote F2 | $6K | |
| ||||||
| Tax withholding / forfeiture | Common Stock | 1,167 | $28.56 | $33K | ||
| Tax withholding / forfeiture | Common Stock | 1,164 | $28.25 | $33K | ||
Recent PHVS Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| VIVIANE ROSINE FRANCOISE BECK MONGES | Director | 11,969 | $396K | View on EDGAR | |
| JOHANNES GER. CHRIS. PE SCHIKAN | Director | 800 |
PHVS insider trading FAQ
What is the latest insider trade for PHVS?
Pharvaris N.V. (PHVS) had 21 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for PHVS runs to 56 Form 4 filings, the earliest from 2026-04-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PHVS stock?
No insider purchases of PHVS were filed in the last 90 days.
How many insiders are selling PHVS stock?
19 insider sales of PHVS were filed in the last 90 days, totaling $20.41M.
Where can I see PHVS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PHVS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Peng Lu view on EDGAR
- - Viviane Monges view on EDGAR
- - Peng Lu view on EDGAR
- - Johannes Gerardus Christiaan Petrus Schikan view on EDGAR
- - David W. Nassif view on EDGAR
- - Peng Lu view on EDGAR
- - Johannes Gerardus Christiaan Petrus Schikan view on EDGAR
- - Elisabeth Bjork view on EDGAR
- - Robert Glassman view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where PHVS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PHVS with a 7-day demo
- PHVS on your watchlist
- Every PHVS Form 4 filing on record
- Up to 3 months of PHVS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive